Results presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients.
C1-INH is a human protein and an important inhibitor of the complement system. Antibody-mediated rejection is a major cause of kidney transplant failure and a prime barrier to improving long-term outcomes for transplant patients. The types of antibody-mediated rejection vary in acuity and severity. Approximately 10 to 15 percent of kidney recipients experience rejection within one year after transplantation.
The placebo-controlled, single-center study evaluated 20 highly sensitized patients, meaning they already had antibodies against donor organs. Subjects were randomized to receive either placebo or 20 IU/kg of C1-INH, administered intra-operatively, then twice a week for seven additional doses. Patients were desensitized with immunoglobulin and rituximab, decreasing the patient's antibody levels prior to transplant.
The study found that post-transplant treatment with C1-INH results in significant increases in the levels of complement components 3 and 4, suggesting that C1-INH inhibits activation of the complement system following transplantation. Antibody-mediated rejection is a major cause of kidney transplant failure and is often associated with activation of complement, a set of proteins that work with antibodies and play a role in the development of inflammation and tissue damage.
According to study findings, fewer patients who were administered C1-INH developed serious adverse events compared to those administered placebo (20 percent versus 30 percent). C1-INH function and antigen levels in blood increased with C1-INH treatment [C1 function (p=0.0007) and C1-INH antigen percent (p=0.013)]. Patients treated with C1-INH experienced increased C3 levels on day 30 (p=0.005), while C4 levels were significantly higher at all time points.
During the study period, no patient treated with C1-INH developed antibody-mediated rejection. Twenty percent of patients developed antibody-mediated rejection following the study period. Thirty percent of patients treated with placebo developed antibody-mediated rejection, ten percent during the study period.
"Antibody-mediated rejection is a severe form of rejection that can occur in patients who have undergone a kidney transplant," said Stanley C. Jordan, M.D., Kidney Transplant, Cedars-Sinai Medical Center in Los Angeles, and one of the study's investigators. "Our findings provide additional insight into how C1-INH affects complement activation and represent an important advance in the study of complement-targeting therapeutics."
This Investigator-Initiated Research study was supported by CSL Behring.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Better Brains With Beer
- How A Former Naturopath Can Help Unravel The Trickery of Alternative Medicine
- Brexit, the EU Now Has its Puerto Rico.
- Tidal Disruption Event: Black Hole Eats Star, Beams Signal To Earth
- 9,000 Years: Origin Of Farmed Rice Gets Pushed Back
- Finding All-Hadronic Top - Again
- Psychiatric Diagnoses Not Valid For African-Americans, Says Sociologist
- "Good news for asteroid defense (it's not new news, but I only found out about it just now), this..."
- "Okay, first, this planet X, if it exists, always remains outside of Neptune if it exists - you..."
- "UPDATE - most recent paper has semimajor axes of ~380–980 AU, and masses of ~5–20..."
- "A better picture might be obtained by reading this article from an Irish journalist based in Russia..."
- "Well, isn’t that just the cat’s whiskers! ..."
- It’s Back to Shots for Flu Prevention
- ACSH Applauds Media Awareness of the Fentanyl Crisis
- Counting Bites Examined, to Help Decrease Food Intake
- The Safe And Unsafe Nutty Treats For Your Pup
- Mr. Potato Head Needs a New Warning Label!
- Shark Finning is Banned in the US; Banning Trade in Fins May Be Next
- Should I stay or should I go?
- New cancer immunotherapy drugs linked to arthritis in some patients
- Simulations foresee hordes of colliding black holes in LIGO's future
- Analysis of genetic repeats suggests role for DNA instability in schizophrenia
- Analysis of media reporting reveals new information about snakebites and how and when they occur